CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

EP: 1.CAR-T in Second-Line DLBCL: When and for Whom?

EP: 2.Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024

EP: 3.CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

EP: 4.Guiding Patients Through CAR T: Key Discussion Points

EP: 5.Future Directions for CAR T-Cell Therapy in LBCL: What’s Next?

EP: 6.Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies

EP: 7.Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

Now Viewing

EP: 8.CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

EP: 9.Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

EP: 10.Key Takeaways: CAR T in Real-World Clinical Practice

Video content above is prompted by the following:

• There were recent data updates on the combination with liso-cel and ibrutinib from the TRANSCEND CLL-004 study at ASH 2024. Dr Ridell, what were some of the data highlights, and has this data influenced your clinical practice?
• In your clinical expertise, is CAR T potentially curative in R/R CLL?
• In your opinion, what does the future look like for CAR T in R/R CLL?